Display options
Share it on

J Med Case Rep. 2010 Mar 31;4:100. doi: 10.1186/1752-1947-4-100.

Prolonged high-dose intravenous magnesium therapy for severe tetanus in the intensive care unit: a case series.

Journal of medical case reports

Menelaos Karanikolas, Dimitrios Velissaris, Markos Marangos, Vassilios Karamouzos, Fotini Fligou, Kriton S Filos

Affiliations

  1. Department of Anaesthesiology and Critical Care Medicine, Patras University Hospital, Rion, 26500, Greece. [email protected].

PMID: 20356376 PMCID: PMC2862042 DOI: 10.1186/1752-1947-4-100

Abstract

INTRODUCTION: Tetanus rarely occurs in developed countries, but it can result in fatal complications including respiratory failure due to generalized muscle spasms. Magnesium infusion has been used to treat spasticity in tetanus, and its effectiveness is supported by several case reports and a recent randomized controlled trial.

CASE PRESENTATIONS: Three Caucasian Greek men aged 30, 50 and 77 years old were diagnosed with tetanus and admitted to a general 12-bed intensive care unit in 2006 and 2007 for respiratory failure due to generalized spasticity. Intensive care unit treatment included antibiotics, hydration, enteral nutrition, early tracheostomy and mechanical ventilation. Intravenous magnesium therapy controlled spasticity without the need for additional muscle relaxants. Their medications were continued for up to 26 days, and adjusted as needed to control spasticity. Plasma magnesium levels, which were measured twice a day, remained in the 3 to 4.5 mmol/L range. We did not observe hemodynamic instability, arrhythmias or other complications related to magnesium therapy in these patients. All patients improved, came off mechanical ventilation, and were discharged from the intensive care unit in a stable condition.

CONCLUSION: In comparison with previous reports, our case series contributes the following meaningful additional information: intravenous magnesium therapy was used on patients already requiring mechanical ventilation and remained effective for up to 26 days (significantly longer than in previous reports) without significant toxicity in two patients. The overall outcome was good in all our patients. However, the optimal dose, optimal duration and maximum safe duration of intravenous magnesium therapy are unknown. Therefore, until more data on the safety and efficacy of magnesium therapy are available, its use should be limited to carefully selected tetanus cases.

References

  1. N Engl J Med. 1995 Mar 23;332(12):812-3 - PubMed
  2. Br Med J. 1979 May 26;1(6175):1401-4 - PubMed
  3. Anaesthesia. 1997 Oct;52(10):956-62 - PubMed
  4. Am J Emerg Med. 1992 Sep;10(5):445-8 - PubMed
  5. Expert Rev Anti Infect Ther. 2008 Jun;6(3):327-36 - PubMed
  6. Anaesthesia. 2002 Aug;57(8):811-7 - PubMed
  7. Intensive Care Med. 1985;11(1):5-12 - PubMed
  8. JAMA. 1978 Aug 18;240(7):675-6 - PubMed
  9. Br J Anaesth. 2002 Jan;88(1):152-3; author reply 153 - PubMed
  10. J R Soc Med. 1994 Mar;87(3):135-7 - PubMed
  11. Anaesthesia. 2003 Mar;58(3):286 - PubMed
  12. Crit Care Med. 1987 Oct;15(10):987-8 - PubMed
  13. Lancet. 2006 Oct 21;368(9545):1436-43 - PubMed
  14. Dis Mon. 1991 Sep;37(9):545-603 - PubMed
  15. Intensive Care Med. 1990;16(2):75-80 - PubMed

Publication Types